Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RCC
MCID: RNL114
MIFTS: 80

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

About this section

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 57
Renal Cell Carcinoma 57 11 19 58 75 73 28 5 14 16 71
Nonpapillary Renal Cell Carcinoma 11 28 5 14
Clear Cell Renal Cell Carcinoma 11 19 58 14
Rcc 57 11 58 73
Clear-Cell Metastatic Renal Cell Carcinoma 11 19 71
Renal Carcinoma, Chromophobe, Somatic 57 12 5
Clear Cell Carcinoma of Kidney 11 28 5
Clear Cell Renal Carcinoma 58 73 16
Adenocarcinoma of Kidney 57 11 73
Hypernephroma 57 11 73
Hereditary Clear Cell Renal Cell Carcinoma 58 71
Conventional Renal Cell Carcinoma 11 71
Conventional Renal Cell Carcinoma 11 73
Renal Cell Carcinoma, Somatic 57 5
Renal Clear Cell Carcinoma 11 53
Carcinoma, Renal Cell 43 38
Ccrcc 58 73
Hereditary Clear Cell Renal Cell Adenocarcinoma 58
Renal Cell Carcinoma, Clear Cell, Somatic 57
Clear Cell Renal Cell Adenocarcinoma 58
Carcinoma, Renal Cell, Nonpapillary 38
Renal Cell Carcinoma Non-Papillary 73
Renal Cell Carcinoma, Clear Cell 57
Clear Cell Kidney Carcinoma 11
Cystic-Multilocular Variant 19
Common Renal Cell Carcinoma 73
Carcinoma Renal Cell 53
Renal Cell Cancer 14
Clear Cell Rcc 19
Crcc 73

Characteristics:


Prevelance:

Renal Cell Carcinoma: 1-5/10000 (Europe) 1-9/100000 (Europe) 58
Clear Cell Renal Carcinoma: 1-9/100000 (Europe) 58

Age Of Onset:

Renal Cell Carcinoma: Adult 58
Clear Cell Renal Carcinoma: Adult,Elderly 58
Hereditary Clear Cell Renal Cell Carcinoma: Adult 58

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 11 DOID:0050387 DOID:4450 DOID:4467
OMIM® 57 144700
MeSH 43 D002292
NCIt 49 C4033 C9385
SNOMED-CT 68 254915003
MESH via Orphanet 44 D002292
ICD10 via Orphanet 32 C64
UMLS via Orphanet 72 C0007134 C0279702
SNOMED-CT via HPO 69 41607009 702391001
UMLS 71 C0007134 C0279702 C1333985 more
Sources

Summaries for Renal Cell Carcinoma, Nonpapillary

About this section

OMIM®: 57 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700) (Updated 08-Dec-2022)

MalaCards based summary: Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to hereditary renal cell carcinoma and renal cell carcinoma, papillary, 1, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is FLCN (Folliculin), and among its related pathways/superpathways is Clear cell renal cell carcinoma pathways. The drugs Sunitinib and Erlotinib have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and cortex, and related phenotypes are renal cell carcinoma and neoplasm

Orphanet 58 Clear cell renal carcinoma: A rare renal tumor arising from proximal tubular epithelial cells of the renal cortex, characterized histologically by malignant epithelial cells with typical clear cytoplasm in conventional staining methods due to a high glycogen and lipid content, featuring a nested growth pattern. Clinically it may present with hematuria, flank pain, anemia or, less commonly, a palpable abdominal mass.

Hereditary clear cell renal cell carcinoma: Hereditary clear cell renal cell carcinoma (ccRCC) is a hereditary renal cancer syndrome defined as development of ccRCC in two or more family members without evidence of constitutional chromosome 3 translocation, von Hippel-Lindau disease or other tumor predisposing syndromes associated with ccRCC, such as tuberous sclerosis or Birt-Hogg-Dubbé syndrome.

GARD: 19 Clear cell renal cell carcinoma is a cancer of the kidney. The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope. Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass). Though the exact cause of Clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.

UniProtKB/Swiss-Prot: 73 Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Disease Ontology 11 Nonpapillary renal cell carcinoma: A hereditary renal cell carcinoma that has material basis in a loss of 3p13-pter sequences.

Renal cell carcinoma: A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Clear cell renal cell carcinoma: A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Wikipedia: 75 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...
Sources

Related Diseases for Renal Cell Carcinoma, Nonpapillary

About this section

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1601)
# Related Disease Score Top Affiliating Genes
1 hereditary renal cell carcinoma 33.9 VHL SDHB RNF139 PBRM1 MET FLCN
2 renal cell carcinoma, papillary, 1 33.7 VHL SETD2 SDHB PBRM1 MTOR MET
3 kidney cancer 33.6 VHL SETD2 SDHB MTOR MIR200C MIR141
4 chromophobe renal cell carcinoma 33.6 VHL SETD2 RNF139 PBRM1 OGG1 MTOR
5 von hippel-lindau syndrome 33.0 VHL SDHB MET LOC107303340 FLCN
6 collecting duct carcinoma 32.8 VHL SETD2 RNF139 PBRM1 OGG1 FLCN
7 birt-hogg-dube syndrome 32.8 SDHB MTOR FLCN
8 cowden syndrome 1 32.8 SDHB MTOR FLCN ATM
9 cowden syndrome 4 32.5 SDHB FLCN
10 clear cell papillary renal cell carcinoma 32.3 PBRM1 HNF1A
11 lung cancer susceptibility 3 32.1 SETD2 OGG1 MIR200C MIR141 MET FHIT
12 kidney angiomyolipoma 31.8 MTOR FLCN
13 cholangiocarcinoma 31.7 PBRM1 OGG1 MTOR MIR141 MET FHIT
14 oncocytoma 31.5 VHL HNF1B FLCN
15 chordoma 31.4 SETD2 PBRM1 MTOR MET
16 inherited cancer-predisposing syndrome 31.3 VHL SDHB MET LOC107303340 FLCN C11orf65
17 bap1 tumor predisposition syndrome 31.3 VHL SDHB MET LOC107303340 FLCN C11orf65
18 cystic kidney disease 31.3 VHL MTOR HNF1B FLCN
19 familial renal papillary carcinoma 31.3 SDHB MET FLCN
20 cowden syndrome 31.3 SDHB MTOR FLCN ATM
21 leiomyomatosis 31.1 VHL SDHB FLCN
22 renal pelvis carcinoma 31.0 SETD2 PBRM1
23 tuberous sclerosis 30.9 VHL MTOR FLCN
24 neurofibromatosis, type i 30.6 VHL SDHB MTOR
25 polycystic kidney disease 4 with or without polycystic liver disease 30.6 MTOR HNF1B HNF1A
26 hematologic cancer 30.6 MTOR MIR200C MIR141 ATM
27 leiomyoma cutis 30.6 SDHB FLCN
28 melanoma, cutaneous malignant 8 11.7
29 multilocular cystic renal neoplasm of low malignant potential 11.6
30 mucinous tubular and spindle renal cell carcinoma 11.5
31 childhood kidney cell carcinoma 11.4
32 eosinophilic variant of chromophobe renal cell carcinoma 11.3
33 multilocular clear cell renal cell carcinoma 11.3
34 renal cell carcinoma, xp11-associated 11.3
35 hereditary conventional renal cell carcinoma 11.3
36 classic variant of chromophobe renal cell carcinoma 11.1
37 tumor predisposition syndrome 1 11.1
38 cowden syndrome 5 11.1
39 cowden syndrome 6 11.1
40 cowden syndrome 7 11.1
41 thyroid carcinoma, papillary, with papillary renal neoplasia 11.0
42 chromophil renal cell carcinoma 11.0
43 exanthem 10.8
44 hypothyroidism 10.8
45 t-cell prolymphocytic leukemia 10.8 MIR200C MIR141 C11orf65 ATM
46 pulmonary embolism 10.7
47 leiomyoma 10.7
48 kidney benign neoplasm 10.7 SDHB MTOR FLCN
49 49, xxxxy syndrome 10.7
50 pancreatic cancer 10.7

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary
Sources

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

About this section

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal cell carcinoma 30 HP:0005584

Clinical features from OMIM®:

144700 (Updated 08-Dec-2022)

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Nonpapillary:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.76 ATM FHIT FLCN MET OGG1 SDHB
2 renal/urinary system MP:0005367 9.56 FLCN HNF1A HNF1B MET MTOR PBRM1
3 immune system MP:0005387 9.44 ATM FHIT FLCN HNF1B HSPBAP1 MET
Sources

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

About this section

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 442)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4 557795-19-4 5329102
2
Erlotinib Approved, Investigational Phase 4 183319-69-9, 183321-74-6 176870
3
Zoledronic acid Approved Phase 4 118072-93-8 68740
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Caffeine Approved Phase 4 58-08-2 2519
10
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
11
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
12
Gemcitabine Approved Phase 4 95058-81-4, 122111-03-9 60750
13
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
14 Angiogenesis Inhibitors Phase 4
15 Protein Kinase Inhibitors Phase 4
16 Pharmaceutical Solutions Phase 4
17 Neurotransmitter Agents Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Adrenergic Agents Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Adrenergic Agonists Phase 4
22 Anesthetics Phase 4
23 Anesthetics, Local Phase 4
24 Hypnotics and Sedatives Phase 4
25 Anesthetics, Intravenous Phase 4
26 Anesthetics, Inhalation Phase 4
27 Anesthetics, General Phase 4
28 Anti-Anxiety Agents Phase 4
29 Psychotropic Drugs Phase 4
30 GABA Modulators Phase 4
31 Analgesics, Opioid Phase 4
32 Bronchodilator Agents Phase 4
33 Adrenergic beta-Agonists Phase 4
34 Anti-Asthmatic Agents Phase 4
35 Vasoconstrictor Agents Phase 4
36 Respiratory System Agents Phase 4
37 Mydriatics Phase 4
38 Sympathomimetics Phase 4
39 Central Nervous System Stimulants Phase 4
40 Phosphodiesterase Inhibitors Phase 4
41
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
42
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
43
Etoposide Approved Phase 3 33419-42-0 36462
44
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
45
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
46
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
47
Lenograstim Approved, Investigational Phase 3 135968-09-1
48
Clonidine Approved Phase 2, Phase 3 4205-91-8, 4205-90-7 2803 20179
49
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
50
Promethazine Approved, Investigational Phase 3 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 1620)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
3 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies Completed NCT00414765 Phase 4 Aldesleukin
5 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Completed NCT02596035 Phase 4 Nivolumab
6 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
7 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
8 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
9 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
10 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
11 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
12 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Completed NCT02982954 Phase 4 Nivolumab;Ipilimumab
13 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
14 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
15 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
16 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
17 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
18 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Recruiting NCT04513522 Phase 4
19 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
20 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02570789 Phase 4 patients with sunitinib or pazopanib
21 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
22 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
23 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
24 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
25 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
26 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
27 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
28 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma Completed NCT02627963 Phase 3 tivozanib hydrochloride;Sorafenib
29 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Completed NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
30 A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma Completed NCT00732914 Phase 3 Sunitinib (Sutent);Sorafenib (Nexavar)
31 Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed NCT00720941 Phase 3 Pazopanib;Sunitinib
32 Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO] Completed NCT00416871 Phase 3
33 An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 Completed NCT00387764 Phase 3 pazopanib
34 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
35 A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. Completed NCT00420888 Phase 2, Phase 3 ABR-217620/naptumomab estafenatox;IFN-alpha
36 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Interferon-Alfa 9MU
37 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
38 An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma Completed NCT00478114 Phase 3 sorafenib
39 A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy Completed NCT00474786 Phase 3 Sorafenib;temsirolimus (Torisel)
40 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
41 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
42 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
43 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
44 An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301). Completed NCT01076010 Phase 3 Tivozanib;Sorafenib
45 A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma. Completed NCT00065468 Phase 3 Interferon Alfa;CCI-779;Interferon Alfa and CCI-779
46 Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma Completed NCT00053807 Phase 3 fluorouracil
47 Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma Completed NCT01613846 Phase 3 Sorafenib+Pazopanib;Pazopanib+Sorafenib
48 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib
49 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma. Completed NCT01064310 Phase 3 pazopanib;sunitinib
50 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1) Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: carcinoma, renal cell

Sources

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

About this section

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 28
2 Nonpapillary Renal Cell Carcinoma 28 FLCN HNF1A HNF1B OGG1 PBRM1 RNF139 VHL
3 Renal Cell Carcinoma 28
Sources

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

About this section

Organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

MalaCards : Kidney, Endothelial, Cortex, Lymph Node, T Cells, Lung, Bone
ODiseA: Kidney
Sources

Publications for Renal Cell Carcinoma, Nonpapillary

About this section

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 37487)
# Title Authors PMID Year
1
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 62 57 5
25911086 2015
2
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 53 57 5
15649945 2005
3
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 53 62 57
20054297 2010
4
Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 53 62 57
11284032 2001
5
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. 53 62 57
10807693 2000
6
Fructose-1,6-bisphosphatase opposes renal carcinoma progression. 62 57
25043030 2014
7
Integrated molecular analysis of clear-cell renal cell carcinoma. 62 57
23797736 2013
8
Comprehensive molecular characterization of clear cell renal cell carcinoma. 62 57
23792563 2013
9
BAP1 loss defines a new class of renal cell carcinoma. 62 57
22683710 2012
10
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. 62 57
21248752 2011
11
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. 62 57
19164706 2009
12
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 53 62 46
18925646 2008
13
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. 62 57
18260086 2008
14
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. 62 57
17539022 2007
15
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. 62 57
17311301 2007
16
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 62 57
16798883 2006
17
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 62 57
16814207 2006
18
Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. 62 57
15016767 2004
19
Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2;3)(q35;q21). 62 57
12939738 2003
20
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 53 57
12837690 2003
21
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. 62 57
12694227 2003
22
Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. 62 57
12872808 2003
23
Understanding familial and non-familial renal cell cancer. 62 57
12351585 2002
24
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. 62 5
11921283 2002
25
Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. 62 57
11776380 2001
26
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. 62 57
10232606 1999
27
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. 62 57
9721855 1998
28
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. 62 57
9689122 1998
29
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. 62 57
9585616 1998
30
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. 53 5
9563489 1998
31
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. 62 57
9461085 1998
32
The Heidelberg classification of renal cell tumours. 62 57
9390023 1997
33
Involvement of multiple loci on chromosome 3 in renal cell cancer development. 62 57
9171996 1997
34
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. 53 5
9140397 1997
35
Renal-cell carcinoma. 62 57
8778606 1996
36
Inhibition of transcription elongation by the VHL tumor suppressor protein. 53 5
7660122 1995
37
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. 62 57
8159756 1994
38
Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 62 57
1433648 1992
39
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. 62 57
1348014 1992
40
Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 62 57
1553556 1992
41
Molecular and cellular characterization of human renal cell carcinoma cell lines. 62 57
1345811 1992
42
The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. 62 57
1685475 1991
43
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. 62 57
1671000 1991
44
Familial renal cell carcinoma: hereditary or coincidental? 62 57
2398557 1990
45
Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. 62 57
1969617 1990
46
A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. 62 57
2914707 1989
47
Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. 62 57
3417313 1988
48
Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. 62 57
3395987 1988
49
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. 62 57
2835149 1988
50
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. 62 57
2894030 1988
Sources

Variations for Renal Cell Carcinoma, Nonpapillary

About this section

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

5 (show top 50) (show all 2167)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CTNNB1 NM_001904.4(CTNNB1):c.1374A>C (p.Glu458Asp) SNV Other
 438755 rs1553631848 GRCh37: 3:41275208-41275208
GRCh38: 3:41233717-41233717
2 MTOR NM_004958.4(MTOR):c.3026G>A (p.Arg1009Gln) SNV Pathogenic
 801436 rs778855567 GRCh37: 1:11288729-11288729
GRCh38: 1:11228672-11228672
3 MET NM_000245.4(MET):c.3562G>T (p.Val1188Leu) SNV Pathogenic
 13882 rs121913669 GRCh37: 7:116422081-116422081
GRCh38: 7:116782027-116782027
4 MET NM_000245.4(MET):c.3682G>A (p.Asp1228Asn) SNV Pathogenic
 13884 rs121913671 GRCh37: 7:116423407-116423407
GRCh38: 7:116783353-116783353
5 MET NM_000245.4(MET):c.3583C>G (p.Leu1195Val) SNV Pathogenic
 13886 rs121913673 GRCh37: 7:116422102-116422102
GRCh38: 7:116782048-116782048
6 HNF1B NM_000458.4(HNF1B):c.46del (p.Leu16fs) DEL Pathogenic
 12648 GRCh37: 17:36104830-36104830
GRCh38: 17:37744839-37744839
7 PBRM1 NM_018313.5(PBRM1):c.3923_3930del (p.Asp1308fs) DEL Pathogenic
 218955 rs864321679 GRCh37: 3:52597380-52597387
GRCh38: 3:52563364-52563371
8 HNF1B NM_000458.4(HNF1B):c.884G>A (p.Arg295His) SNV Pathogenic
 288154 GRCh37: 17:36091747-36091747
GRCh38: 17:37731756-37731756
9 OGG1 NM_002542.6(OGG1):c.137G>A (p.Arg46Gln) SNV Pathogenic
 7602 rs104893751 GRCh37: 3:9792107-9792107
GRCh38: 3:9750423-9750423
10 FLCN FLCN, 2-BP DEL, 1284TC AND 2-BP INS, 1284AC INDEL Pathogenic
 3368 GRCh37:
GRCh38:
11 HNF1A NM_000545.8(HNF1A):c.1340C>T (p.Pro447Leu) SNV Pathogenic
 14928 rs137853236 GRCh37: 12:121435307-121435307
GRCh38: 12:120997504-120997504
12 LOC107303340, VHL NM_000551.4(VHL):c.530_536del (p.Arg177fs) DEL Pathogenic
 694389 rs1575932266 GRCh37: 3:10191534-10191540
GRCh38: 3:10149850-10149856
13 LOC107303340, VHL NM_000551.4(VHL):c.548C>A (p.Ser183Ter) SNV Pathogenic
 2215 rs5030823 GRCh37: 3:10191555-10191555
GRCh38: 3:10149871-10149871
14 SDHB NM_003000.3(SDHB):c.661del (p.Asp221fs) DEL Pathogenic
 1723187 GRCh37: 1:17349207-17349207
GRCh38: 1:17022712-17022712
15 ATM, C11orf65 NM_000051.4(ATM):c.8671+2_8671+3insTA INSERT Pathogenic
 3037 GRCh37: 11:108218094-108218095
GRCh38: 11:108347367-108347368
16 MET NM_000245.4(MET):c.3392T>C (p.Met1131Thr) SNV Pathogenic
Pathogenic
 13881 rs121913668 GRCh37: 7:116418881-116418881
GRCh38: 7:116778827-116778827
17 MET NM_000245.4(MET):c.3658G>A (p.Val1220Ile) SNV Pathogenic
Likely Pathogenic
 13883 rs121913670 GRCh37: 7:116423383-116423383
GRCh38: 7:116783329-116783329
18 MET NM_000245.4(MET):c.3689A>G (p.Tyr1230Cys) SNV Pathogenic
Uncertain Significance
 13885 rs121913246 GRCh37: 7:116423414-116423414
GRCh38: 7:116783360-116783360
19 MET NM_000245.4(MET):c.3281A>G (p.His1094Arg) SNV Pathogenic
Pathogenic
 13887 rs121913243 GRCh37: 7:116417464-116417464
GRCh38: 7:116777410-116777410
20 HNF1A NM_000545.8(HNF1A):c.872dup (p.Gly292fs) DUP Pathogenic
 14927 rs587776825 GRCh37: 12:121432117-121432118
GRCh38: 12:120994314-120994315
21 HNF1A NM_000545.8(HNF1A):c.92G>A (p.Gly31Asp) SNV Pathogenic
Pathogenic
Uncertain Significance
 14948 rs137853247 GRCh37: 12:121416663-121416663
GRCh38: 12:120978860-120978860
22 MET NM_000245.4(MET):c.3274G>A (p.Val1092Ile) SNV Pathogenic
Pathogenic
 186141 rs786202724 GRCh37: 7:116417457-116417457
GRCh38: 7:116777403-116777403
23 HNF1A NM_000545.8(HNF1A):c.814C>T (p.Arg272Cys) SNV Pathogenic
 447503 rs1555212014 GRCh37: 12:121432067-121432067
GRCh38: 12:120994264-120994264
24 HNF1A NM_000545.8(HNF1A):c.1135C>G (p.Pro379Ala) SNV Pathogenic
 431970 rs754729248 GRCh37: 12:121434371-121434371
GRCh38: 12:120996568-120996568
25 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter) SNV Pathogenic
 253251 rs879255678 GRCh37: 17:17118502-17118502
GRCh38: 17:17215188-17215188
26 LOC107303340, VHL NM_000551.4(VHL):c.499C>T (p.Arg167Trp) SNV Pathogenic
Pathogenic
Likely Pathogenic
 2218 rs5030820 GRCh37: 3:10191506-10191506
GRCh38: 3:10149822-10149822
27 VHL NM_000551.4(VHL):c.257C>G (p.Pro86Arg) SNV Pathogenic
 223170 rs730882034 GRCh37: 3:10183788-10183788
GRCh38: 3:10142104-10142104
28 ATM, C11orf65 NM_000051.4(ATM):c.9019G>T (p.Glu3007Ter) SNV Pathogenic
 233403 rs876660382 GRCh37: 11:108236083-108236083
GRCh38: 11:108365356-108365356
29 LOC107303340, VHL NM_000551.4(VHL):c.464-2A>G SNV Pathogenic
 223222 rs5030816 GRCh37: 3:10191469-10191469
GRCh38: 3:10149785-10149785
30 LOC107303340, VHL NM_000551.4(VHL):c.481C>T (p.Arg161Ter) SNV Pathogenic
Likely Pathogenic
 2217 rs5030818 GRCh37: 3:10191488-10191488
GRCh38: 3:10149804-10149804
31 LOC107303340, VHL NM_000551.4(VHL):c.598C>T (p.Arg200Trp) SNV Pathogenic
 2232 rs28940298 GRCh37: 3:10191605-10191605
GRCh38: 3:10149921-10149921
32 BAP1 NM_004656.4(BAP1):c.535C>T (p.Arg179Trp) SNV Likely Pathogenic
 861467 rs910211860 GRCh37: 3:52441235-52441235
GRCh38: 3:52407219-52407219
33 FLCN NM_144997.7(FLCN):c.779+1G>T SNV Likely Pathogenic
 231274 rs758175953 GRCh37: 17:17125814-17125814
GRCh38: 17:17222500-17222500
34 VHL NM_000551.4(VHL):c.319C>G (p.Arg107Gly) SNV Likely Pathogenic
 43599 rs397516440 GRCh37: 3:10183850-10183850
GRCh38: 3:10142166-10142166
35 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
36 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Likely Pathogenic
 39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
37 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely Pathogenic
 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
38 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
 376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
39 TP53 NM_000546.6(TP53):c.659A>C (p.Tyr220Ser) SNV Likely Pathogenic
 12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
40 PTEN NM_000314.8(PTEN):c.388C>G (p.Arg130Gly) SNV Likely Pathogenic
 375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
41 VHL NM_000551.4(VHL):c.266T>A (p.Leu89His) SNV Likely Pathogenic
 376047 rs5030807 GRCh37: 3:10183797-10183797
GRCh38: 3:10142113-10142113
42 TP53 NM_000546.6(TP53):c.422G>T (p.Cys141Phe) SNV Likely Pathogenic
 376568 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
43 TP53 NM_000546.6(TP53):c.721T>C (p.Ser241Pro) SNV Likely Pathogenic
 376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
44 TP53 NM_000546.6(TP53):c.614A>T (p.Tyr205Phe) SNV Likely Pathogenic
 376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
45 TP53 NM_000546.6(TP53):c.421T>A (p.Cys141Ser) SNV Likely Pathogenic
 376567 rs1057519978 GRCh37: 17:7578509-7578509
GRCh38: 17:7675191-7675191
46 TP53 NM_000546.6(TP53):c.824G>T (p.Cys275Phe) SNV Likely Pathogenic
 376582 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
47 TP53 NM_000546.6(TP53):c.614A>C (p.Tyr205Ser) SNV Likely Pathogenic
 376683 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
48 TP53 NM_000546.6(TP53):c.613T>G (p.Tyr205Asp) SNV Likely Pathogenic
 376686 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
49 TP53 NM_000546.6(TP53):c.526T>A (p.Cys176Ser) SNV Likely Pathogenic
 376570 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
50 TP53 NM_000546.6(TP53):c.638G>T (p.Arg213Leu) SNV Likely Pathogenic
 376650 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

73
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

8 (show top 50) (show all 7535)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM85360217 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176= 3:124737785-124737785 63
2 COSM93517001 TRIO kidney,NS,carcinoma,renal cell c.1505A>G p.N502S 5:14508136-14508136 63
3 COSM143919608 TRIO kidney,NS,carcinoma,renal cell c.706-1273A>G p.? 5:14508136-14508136 63
4 COSM89062698 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 63
5 COSM90865192 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 63
6 COSM94389604 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 63
7 COSM94442225 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 63
8 COSM94492333 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 63
9 COSM92824042 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 63
10 COSM94232725 RABGAP1 kidney,NS,carcinoma,renal cell c.1749T>A p.H583Q 9:123020414-123020414 63
11 COSM106795558 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
12 COSM130825760 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
13 COSM94057597 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
14 COSM126664114 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
15 COSM131800227 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
16 COSM114430588 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 63
17 COSM100863866 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 63
18 COSM129143197 KMT2A kidney,NS,carcinoma,renal cell c.5720C>T p.A1907V 11:118497991-118497991 63
19 COSM144159091 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 63
20 COSM96915510 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 63
21 COSM86472399 H2BC1 kidney,NS,carcinoma,renal cell c.239C>A p.S80* 6:25727147-25727147 63
22 COSM146087884 DOCK1 kidney,NS,carcinoma,renal cell c.1369G>T p.D457Y 10:127023241-127023241 63
23 COSM88845534 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 63
24 COSM102230151 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 63
25 COSM137305195 DDX19B kidney,NS,carcinoma,renal cell c.558G>A p.V186= 16:70325624-70325624 63
26 COSM137613380 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 63
27 COSM136951592 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 63
28 COSM88298617 DDX19B kidney,NS,carcinoma,renal cell c.543G>A p.V181= 16:70325624-70325624 63
29 COSM92903161 DDX19B kidney,NS,carcinoma,renal cell c.450G>A p.V150= 16:70325624-70325624 63
30 COSM111962535 DDX19B kidney,NS,carcinoma,renal cell c.465G>A p.V155= 16:70325624-70325624 63
31 COSM125364846 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 63
32 COSM88086191 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 63
33 COSM120703070 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 63
34 COSM122317683 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 63
35 COSM95279694 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 63
36 COSM129930398 ARHGAP20 kidney,NS,carcinoma,renal cell c.1277A>G p.D426G 11:110586276-110586276 63
37 COSM128048829 ARHGAP20 kidney,NS,carcinoma,renal cell c.1247A>G p.D416G 11:110586276-110586276 63
38 COSM130426538 ARHGAP20 kidney,NS,carcinoma,renal cell c.-17A>G p.? 11:110586276-110586276 63
39 COSM127507491 ARHGAP20 kidney,NS,carcinoma,renal cell c.1286A>G p.D429G 11:110586276-110586276 63
40 COSM85547904 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 63
41 COSM128420528 ARHGAP20 kidney,NS,carcinoma,renal cell c.1247A>G p.D416G 11:110586276-110586276 63
42 COSM111167644 kidney,NS,carcinoma,renal cell c.160+10669G>A p.? 16:70325624-70325624 63
43 COSM143616890 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2108A>C p.Q703P 2:184937759-184937759 42
44 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 42
45 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 42
46 COSM143612455 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.-135G>C p.? 2:184866378-184866378 42
47 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 42
48 COSM100946000 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 42
49 COSM85796182 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 42
50 COSM144685741 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 42

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

6 (show top 50) (show all 1300)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 42189 10 3000000 17300000 Copy number Renal cell carcinoma
14 42932 10 42300000 52900000 Copy number Renal cell carcinoma
15 49432 11 106916419 134173875 Loss Renal cell carcinoma
16 49705 11 110400000 121200000 Copy number Renal cell carcinoma
17 51840 11 13182721 13183721 Gain Renal cell carcinoma
18 51843 11 13184856 13185856 Loss Renal cell carcinoma
19 52861 11 21000000 57000000 Gain Renal cell carcinoma
20 53056 11 23642584 23643584 Gain Renal cell carcinoma
21 53595 11 31000000 43500000 Copy number Renal cell carcinoma
22 53953 11 35317771 35318771 Gain Renal cell carcinoma
23 60490 11 87000000 107000000 Gain Renal cell carcinoma
24 64438 12 12800000 14800000 Copy number Renal cell carcinoma
25 67031 12 35000000 69000000 Gain Renal cell carcinoma
26 67043 12 35400000 132349534 Gain Renal cell carcinoma
27 69398 12 54900000 58100000 Copy number Renal cell carcinoma
28 72532 12 82000000 100000000 Gain Renal cell carcinoma
29 75379 13 19500000 23300000 Loss Renal cell carcinoma
30 75593 13 21548578 21635655 Copy number Renal cell carcinoma
31 82801 14 15600000 106368585 Copy number Renal cell carcinoma
32 82818 14 15600000 106368585 Loss Renal cell carcinoma
33 83187 14 19387587 106241517 Loss Renal cell carcinoma
34 85229 14 41000000 48000000 Gain Renal cell carcinoma
35 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
36 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
37 88312 14 89800000 91900000 Copy number Renal cell carcinoma
38 89170 15 100153615 100154615 Gain Renal cell carcinoma
39 90158 15 20233523 20234523 Gain Renal cell carcinoma
40 90187 15 20359182 20360182 Gain Renal cell carcinoma
41 90188 15 20359229 20360229 Gain Renal cell carcinoma
42 90209 15 20439260 20440260 Loss Renal cell carcinoma
43 90210 15 20442152 20442452 Loss Renal cell carcinoma
44 90214 15 20449913 20450913 Gain Renal cell carcinoma
45 33893 1 5000000 7000000 Loss Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma
Sources

Expression for Renal Cell Carcinoma, Nonpapillary

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma, Nonpapillary patients vs. healthy controls: 35 (show top 50) (show all 277)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SLC12A1 solute carrier family 12 member 1 Kidney - 9.35 0.000
2 CALB1 calbindin 1 Kidney - 8.95 0.000
3 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 8.29 0.000
4 CLDN8 claudin 8 Kidney - 8.20 0.000
5 KCNJ1 potassium inwardly rectifying channel subfamily J member 1 Kidney - 8.20 0.000
6 NPHS2 NPHS2 stomatin family member, podocin Kidney - 8.18 0.000
7 MUC15 mucin 15, cell surface associated Kidney - 7.96 0.000
8 SCNN1G sodium channel epithelial 1 subunit gamma Kidney - 7.91 0.000
9 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 7.78 0.000
10 FABP1 fatty acid binding protein 1 Kidney - 7.74 0.000
11 DNASE1 deoxyribonuclease 1 Kidney - 7.59 0.000
12 SLC7A13 solute carrier family 7 member 13 Kidney - 7.29 0.000
13 ANGPTL4 angiopoietin like 4 Kidney + 7.25 0.000
14 TNFAIP6 TNF alpha induced protein 6 Kidney + 7.16 0.000
15 ATP6V0A4 ATPase H+ transporting V0 subunit a4 Kidney - 7.13 0.000
16 PCP4 Purkinje cell protein 4 Kidney - 7.13 0.000
17 KNG1 kininogen 1 Kidney - 7.12 0.000
18 TYRP1 tyrosinase related protein 1 Kidney - 7.10 0.000
19 FGF9 fibroblast growth factor 9 Kidney - 6.99 0.000
20 EGF epidermal growth factor Kidney - 6.92 0.000
21 RALYL RALY RNA binding protein like Kidney - 6.81 0.000
22 PVALB parvalbumin Kidney - 6.73 0.000
23 KCNJ10 potassium inwardly rectifying channel subfamily J member 10 Kidney - 6.69 0.000
24 TMEM213 transmembrane protein 213 Kidney - 6.64 0.000
25 SLC22A8 solute carrier family 22 member 8 Kidney - 6.58 0.000
26 IRX2 iroquois homeobox 2 Kidney - 6.56 0.000
27 SLC26A7 solute carrier family 26 member 7 Kidney - 6.56 0.000
28 SLC4A1 solute carrier family 4 member 1 (Diego blood group) Kidney - 6.53 0.000
29 GPC5 glypican 5 Kidney - 6.53 0.000
30 RHCG Rh family C glycoprotein Kidney - 6.52 0.000
31 SOST sclerostin Kidney - 6.51 0.000
32 SFRP1 secreted frizzled related protein 1 Kidney - 6.49 0.000
33 HEPACAM2 HEPACAM family member 2 Kidney - 6.45 0.000
34 NELL1 neural EGFL like 1 Kidney - 6.38 0.000
35 SERPINA5 serpin family A member 5 Kidney - 6.34 0.000
36 RAB25 RAB25, member RAS oncogene family Kidney - 6.32 0.000
37 TMPRSS2 transmembrane serine protease 2 Kidney - 6.31 0.000
38 TMEM52B transmembrane protein 52B Kidney - 6.28 0.000
39 ERBB4 erb-b2 receptor tyrosine kinase 4 Kidney - 6.26 0.000
40 SOSTDC1 sclerostin domain containing 1 Kidney - 6.25 0.000
41 SH3GL2 SH3 domain containing GRB2 like 2, endophilin A1 Kidney - 6.16 0.000
42 ALDOB aldolase, fructose-bisphosphate B Kidney - 6.13 0.003
43 APOC1 apolipoprotein C1 Kidney + 6.11 0.000
44 UMOD uromodulin Kidney - 6.07 0.000
45 NPTX2 neuronal pentraxin 2 Kidney + 6.05 0.000
46 MFSD4A-AS1 MFSD4A antisense RNA 1 Kidney - 6.02 0.000
47 ESRRB estrogen related receptor beta Kidney - 5.99 0.000
48 SLC13A3 solute carrier family 13 member 3 Kidney - 5.96 0.001
49 TSPAN8 tetraspanin 8 Kidney - 5.96 0.000
50 WNK4 WNK lysine deficient protein kinase 4 Kidney - 5.94 0.000
Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.
Sources

Pathways for Renal Cell Carcinoma, Nonpapillary

About this section

Pathways related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Clear cell renal cell carcinoma pathways 74
10.85 VHL SETD2 PBRM1 MTOR
Sources

GO Terms for Renal Cell Carcinoma, Nonpapillary

About this section

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of autophagy GO:0010507 9.8 VHL MTOR MET
2 cellular response to leucine GO:0071233 9.58 MTOR HNF1A
3 regulation of cellular response to stress GO:0080135 9.43 MTOR ATM
4 pancreas development GO:0031016 9.43 MET HNF1B HNF1A
5 positive regulation of response to stimulus GO:0048584 9.37 MTOR ATM
6 response to stress GO:0006950 9.26 MTOR ATM
7 regulation of nucleobase-containing compound metabolic process GO:0019219 9.16 ATM MTOR
8 regulation of pronephros size GO:0035565 8.8 HNF1B HNF1A
Sources

Sources for Renal Cell Carcinoma, Nonpapillary

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....